Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Praxis Precision Medicines, Inc. (PRAX)

Caris Life Sciences,�Inc. and Praxis Precision Medicines, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and Praxis Precision Medicines, Inc. are of similar size ($7.4B and $7.3B). Praxis Precision Medicines, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 73.9×. Praxis Precision Medicines, Inc. grew revenue faster over the last twelve months: 249.5% against 68.8%. Caris Life Sciences,�Inc. has the higher net margin (9.16% vs 0.00%) and the higher return on invested capital (33.0% vs −40.6%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 12 and Praxis Precision Medicines, Inc. on 5.

Valuation

Metric CAI PRAX Biotechnology median
P/E 73.94 n/m 10.60
P/S 6.80 942.59 9.40
P/B 11.15 6.01 2.13
Price to free cash flow 246.58 n/m 25.18
EV/EBITDA 40.62 n/m 0.66
EV/Sales 6.44 853.91 9.02
Earnings yield 1.35% (4.67%) (32.88%)
Free cash flow yield 0.41% (3.80%) (23.13%)

Profitability

Metric CAI PRAX Biotechnology median
Gross margin 69.09% 100.00% 68.51%
Operating margin 13.35% 0.00% 0.00%
Net margin 9.16% 0.00% 0.00%
Free cash flow margin 2.76% 0.00% 0.00%
Return on equity 17.19% (38.86%) (51.96%)
Return on assets 8.58% (36.80%) (46.06%)
Return on invested capital 32.96% (40.58%) 0.00%

Growth

Metric CAI PRAX Biotechnology median
Revenue growth (TTM) 68.84% 249.53% 6.76%
EPS growth (last fiscal year) 69.79% (32.03%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI PRAX Biotechnology median
Debt to equity 0.62 0.00 0.00
Current ratio 6.71 15.73 4.97
Net debt to EBITDA (5.23) 1.82 1.01

Dividend

Metric CAI PRAX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAI PRAX Biotechnology median
Market cap 7.36b 7.33b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack